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Aim: To identify factors associated with documented symptomatic and severe hypoglycaemia
over 4 years in people with type 2 diabetes starting insulin therapy.
Materials and methods: CREDIT, a prospective international observational study, collected data
over 4 years on people starting any insulin in 314 centres; 2729 and 2271 people had hypogly-
caemia data during the last 6 months of years 1 and 4, respectively. Multivariable logistic
regression was used to select the characteristics associated with documented symptomatic
hypoglycaemia, and the model was tested against severe hypoglycaemia.
Results: The proportions of participants reporting ≥1 non-severe event were 18.5% and 16.6%
in years 1 and 4; the corresponding proportions of those achieving a glycated haemoglobin
(HbA1c) concentration <7.0% (<53 mmol/mol) were 24.6% and 18.3%, and 16.5% and 16.2%
of those who did not. For severe hypoglycaemia, the proportions were 3.0% and 4.6% of peo-
ple reaching target vs 1.5% and 1.1% of those not reaching target. Multivariable analysis
showed that, for documented symptomatic hypoglycaemia at both years 1 and 4, baseline
lower body mass index and more physical activity were predictors, and lower HbA1c was an
explanatory variable in the respective year. Models for documented symptomatic hypoglycae-
mia predicted severe hypoglycaemia. Insulin regimen was a univariate explanatory variable, and
was not retained in the multivariable analysis.
Conclusions: Hypoglycaemia occurred at significant rates, but was stable over 4 years despite
increased insulin doses. The association with insulin regimen and with oral agent use declined
over that time. Associated predictors and explanatory variables for documented symptomatic
hypoglycaemia conformed to clinical impressions and could be extended to severe hypoglycae-
mia. Better achieved HbA1c was associated with a higher risk of hypoglycaemia.
KEYWORDS
CREDIT, documented symptomatic hypoglycaemia, multivariable analysis, severe
hypoglycaemia, type 2 diabetes mellitus
1 | INTRODUCTION
Good blood glucose control can prevent microvascular complications in
people with type 2 diabetes, and there is some evidence that it may pre-
vent or slow the progression of cardiovascular diseases.1–4 People with
type 2 diabetes can often maintain adequate glycaemic control with
appropriate lifestyle and oral glucose-lowering drugs (OGLDs), but timely
introduction of injection therapy is indicated when glycaemic control is no
longer maintained.5–7 There is often reluctance, however, to start insulin
therapy on the part of both the clinician and the individual with type 2 dia-
betes because of the need for injections, fear of hypoglycaemia and
weight gain and increased complexity of therapy.8–10
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The Cardiovascular Risk Evaluation in people with type 2 Diabe-
tes on Insulin Therapy (CREDIT) study aimed to evaluate both the
relationship between blood glucose control and cardiovascular events
prospectively over 4 years in a large cohort of people starting insulin
therapy, and to provide insight into routine clinical practice in the
management of people with type 2 diabetes using insulin.11,12 In an
earlier report, we described the evolution of insulin use, associated
blood glucose-related outcomes and effects on body weight and
hypoglycaemia over the 4 years of the study.13
In the present study, we aimed to: (1) evaluate the characteris-
tics, both at 1 year and 4 years, that were associated with documen-
ted symptomatic hypoglycaemia; (2) understand the nature of those
relationships in routine care, particularly for glucose control; (3) dis-
cover if those characteristics would apply to severe hypoglycaemia;
and (4) understand how the evolution of insulin regimen (and oral
agents) and insulin dose affected hypoglycaemia rates. Previously, we
have reported the characteristics of people in the CREDIT study that
are associated with weight gain,14 and those associated with good
glycaemic control,15 and described the relationship between blood
glucose control and cardiovascular events.16
2 | MATERIALS AND METHODS
The CREDIT study design, participant selection criteria and partici-
pant characteristics have been reported previously.11,12 In brief, the
study involved 314 centres in 12 countries, 10 in Europe, plus
Canada and Japan. Men and women with type 2 diabetes, aged
>40 years, who had started any insulin therapy within 12 months and
who had a glycated haemoglobin (HbA1c) measurement ≤3 months
before beginning insulin were eligible for inclusion. As a non-
interventional study, there was no fixed study visit schedule, and
insulin choice, dosage, titration, medical costs and concomitant oral
agent therapy were according to usual local practice. Ongoing data
were gathered prospectively in routine clinical practice, and the treat-
ing physicians were asked to report, according to protocol, updated
data every 6 months. The results presented here as the 1- and 4-year
follow-up data are those provided during the 9 to 18-month and
42 to 54-month windows after starting insulin.
Hypoglycaemia data for the 6 months prior to the annual follow-
up date were collected from patient records and patient recall on
structured report forms. Documented symptomatic hypoglycaemia
was any non-severe event with clinical symptoms resulting in hypo-
glycaemia confirmed by self-monitored plasma glucose concentra-
tion ≤ 3.9 mmol/L.17 Severe hypoglycaemia was any event requiring
the assistance of another person and confirmed by self-monitored
plasma glucose <2.0 mmol/L or prompt recovery after oral carbohy-
drate, intravenous glucose or intramuscular glucagon.17 Updated
mean HbA1c was the average of HbA1c measurements from 1 month
after beginning insulin up to follow-up year values.
Local ethics approval was obtained for all sites, and standards of
study conduct were according to the Declaration of Helsinki. Written
informed consent was obtained from all participants in advance.
A statistical analysis plan was developed prior to data analysis.
The principal outcome measure was the occurrence of documented
symptomatic hypoglycaemia in any participant over the 6 months
before the year 1 and year 4 follow-up visits. Variables prespecified
at the start of insulin therapy, as candidate predictors of documented
symptomatic hypoglycaemia, were: age; gender; weight; body mass
index (BMI); waist circumference; systolic blood pressure (SBP); dia-
stolic blood pressure (DBP); diabetes duration; family history of type
2 diabetes in first-degree relatives; previous diagnosis of high blood
pressure; physical activity (yes/no); micro- and macrovascular disease;
family history of premature cardiovascular disease; estimated glomer-
ular filtration rate (Cockcroft–Gault formula); urinary albumin; urinary
albumin/creatinine ratio; HbA1c; fasting plasma glucose; postprandial
plasma glucose; starting insulin regimen (basal insulin alone, basal plus
short-acting insulin, short-acting insulin, premixed insulin, other);
insulin dose; and OGLDs (none, including a sulphonylurea or no sul-
phonylurea). Physical activity (yes) was defined as ≥4 hours a week.
Additional variables were: height; heart rate; lifestyle (alone/not
alone); serum LDL cholesterol; HDL cholesterol; triglycerides; serum
creatinine; smoking (current and stopped <1 year/never or stopped
≥1 year); who advised insulin (primary care/secondary care); and
whether insulin started as inpatient or not.
The following variables at years 1 or 4 were seen as potential
explanatory factors: body weight; BMI; SBP; DBP; creatinine clear-
ance; albuminuria; HbA1c; change from baseline HbA1c; fasting
plasma glucose; change from baseline fasting plasma glucose; post-
prandial plasma glucose; change from baseline postprandial plasma
glucose; insulin regimen (as above); insulin dose; and OGLD use
(as above). For year 4 analyses, new microvascular disease, new
macrovascular disease or both during follow-up were included, as
defined previously.11
2.1 | Statistical methods
Analyses were performed using SAS statistical suite version 9.2 or
higher (SAS Institute, Cary, NC, USA). Descriptive statistics (hypogly-
caemia incidence [proportion of population affected] and event rate)
were obtained according to insulin regimen and HbA1c target
achievement (<7.0% [<53 mmol/mol]; ≥7.0% [≥53 mmol/mol]) and
overall. The functional form of the continuous predictive variables
was determined in logistic regression models adjusted for region
(Eastern Europe: Croatia, Ukraine, Russia; Southern Europe: Italy, Por-
tugal, Spain; France; Northern Europe: United Kingdom, Finland, Ger-
many; Japan; Canada), by comparing the Akaike Information Criterion
for models with the predictive variables in linear, loge and restricted
cubic spline forms. The preferred model was selected from a model
that only included region, with a criterion for improvement ≥3.84 for
each step.14 No variables required transformation, except at year
4 when baseline DBP and current HbA1c and change from baseline
HbA1c fitted best to restricted cubic splines.
Single variable analyses used logistic regression models, adjusted
for region. For multivariable analyses, variables with ≤20% of missing
data were included in a logistic regression model with region forced
into the model. Variables were selected stepwise with a significance
level for entry of 20% and for removal of 5%. For restricted cubic
spline variables, the whole of the restricted cubic spline together was
considered, rather than considering individual terms separately, and
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target values were used for the reference level. Model 1 included var-
iables when beginning insulin, and model 2 included baseline vari-
ables retained in model 1 together with the year 1 (or year 4)
explanatory variables. Model 3 included all baseline and year
1 (or year 4) explanatory variables.
To identify whether the smaller incidence of severe hypoglycaemia
is consistent with the findings for documented symptomatic hypogly-
caemia, a risk-factor score for year 1 (and year 4) was produced using
all variables retained in the final model 1 (baseline variables) for docu-
mented symptomatic hypoglycaemia at year 1 or 4 (including region).
The model prediction (fitted value) was used as a single explanatory
variable for the severe hypoglycaemia model 1 at years 1 and
4, respectively. Similarly, severe hypoglycaemia models 2 and 3 used
all retained variables in the documented symptomatic hypoglycaemia
models 2 and 3. However, the last analysis was performed only if
models 2 and 3 on documented symptomatic hypoglycaemia differed.
Supportive analyses were performed for all models using region and
all main variables (see above) when starting insulin for the risk factor
score in model 1, all variables retained in the final model 1 plus all
other explanatory variables at year 1 or 4 in model 2, and all main
variables at baseline and all other explanatory variables at year 1 or
4 in model 3.
3 | RESULTS
3.1 | Glucose control and insulin regimens
Detailed core study results of glucose control and changes in insulin
regimen are given elsewhere.13 Basal insulin and mealtime insulin
usage declined over the 4 years, use of basal plus mealtime insulin
increased and premixed insulin usage remained relatively constant.13
The mean (SD) total daily doses of insulin at years 1 and 4 were
0.43 (0.25) and 0.54 (0.31) U/kg, and the mean (SD) HbA1c concen-
trations were 7.7 (1.4)% (61 [15] mmol/mol) and 7.6 (1.3)%
(60 [14] mmol/mol), respectively. Fasting plasma glucose concentra-
tions were 8.0 (2.5) mmol/L at year 1 and 7.7 (2.4) mmol/L at year
4, and postprandial plasma glucose concentrations were 9.7 (3.2) and
9.4 (3.2) mmol/L, respectively. Dose and HbA1c data for individual
insulin regimens are given in the Supporting Information, Table S1.
3.2 | Hypoglycaemia incidence and event rates
A total of 2729 and 2271 people had data on hypoglycaemia during
the last 6 months of years 1 and 4 of follow-up, respectively. The
proportions of participants (incidence) with documented symptomatic
hypoglycaemia in the 6 months before the year 1 and 4 follow-up
visits, respectively, were: 15.0% and 14.9% for those on basal insulin;
21.4% and 18.6% for those on basal plus mealtime insulin; 19.3% and
14.8% for those on mealtime insulin; 21.3% and 19.1% on premixed
insulin; 22.4% and 15.8% on other insulin; and 8.9% and 2.5% for
those who reported no insulin use.
For all insulin regimens together, the proportions of people
reporting at least one documented symptomatic hypoglycaemia event
were 18.5% and 16.6% for the year 1 and year 4 follow-up, and
24.6% and 18.3%, respectively, for those achieving updated mean
HbA1c <7.0% (<53 mmol/mol) and 16.5% and 16.2% for those who
did not. The proportions of people who reported one or more severe
hypoglycaemic events for these half-yearly follow-up periods were
1.9% and 2.0% overall, 3.0% and 4.6% for those who achieved the
HbA1c target, and 1.5% and 1.1% for those who did not.
Within different classifications of hypoglycaemia (documented
symptomatic hypoglycaemia or severe hypoglycaemia, nocturnal or
anytime), event rates were similar across years 1 to 4, and by insulin
regimen (Table 1). The mean (range) rate for documented symptomatic
hypoglycaemia was ~0.99 (0.85-1.05) events/person in the 6-month
period, and for nocturnal documented symptomatic hypoglycaemia it
was ~0.15 (0.13-0.21) events/person in the 6-month period (Table 1).
The event rate for severe hypoglycaemia was less certain, with a range
of 0.03 to 0.08 events/person in the 6-month period anytime, and
0.01 to 0.02 events/person in the 6-month period at night (Table 1).
The rate of documented symptomatic hypoglycaemia was greater for
those who achieved updated mean HbA1c <7.0% (<53 mmol/mol)
than for those who did not (1.18-1.40 vs 0.75-0.96 events/person in
the 6-month period), the same being true for nocturnal documented
symptomatic hypoglycaemia (0.14-0.24 vs 0.12-0.20 events/person in
the 6-month period). For severe hypoglycaemia there were 0.04 to
0.20 vs 0.02 to 0.04 events/person in the 6-month period for people
with updated mean HbA1c <7.0% vs HbA1c ≥7.0%, while for severe
hypoglycaemia at night there were 0.02 to 0.06 vs 0.00 to 0.01
events/person in the 6-month period. Severe hypoglycaemia was rare
in those people who did not have a documented symptomatic hypogly-
caemic event in the same period, with 3/2225 people experiencing this
at 1 year and 3/1895 at 4 years.
3.3 | Predictors and explanatory factors for
hypoglycaemia
Univariate analysis identified 9 variables when starting insulin and
9 variables at year 1 that were associated with documented symp-
tomatic hypoglycaemia at year 1 (Table 2). The number of variables
associated with documented symptomatic hypoglycaemia at year
4 was 8 when starting insulin and 5 at year 4 (Table 3). Baseline vari-
ables that were found in common in years 1 and 4 were body weight,
BMI and physical activity. Variables in common at both visit years
were change in body weight, mean HbA1c (from 6 months before to
1 month after nominal visit date), change in HbA1c and insulin
regimen.
Multivariable analysis for documented symptomatic hypoglycae-
mia at year 1 identified the following predictor baseline variables:
lower BMI; physical activity (yes); and no prior OGLDs vs sulphony-
lurea use (Figure 1). Model-selected explanatory variables measured
at year 1 were lower HbA1c, higher total insulin dose and sulphony-
lurea use vs no OGLDs.
For documented symptomatic hypoglycaemia at year 4, the base-
line predictor variables retained were physical activity (yes), prior
macrovascular disease, lower BMI, lower HbA1c and high DBP
(Figure 1). The odds ratio (OR; reference 1.00 for DBP 85 mm Hg)
was increased at higher DBP (Figure 1). Additional retained variables
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from measurements at 4 years were higher total insulin dose (model
2 but not model 3, OR 1.05 [1.01; 1.10] per 0.1 U/kg/d), higher SBP,
and updated HbA1c (Figure 1). The OR (reference 1.00 for HbA1c
7.0%) increased for lower HbA1c at 4 years, and substantially
decreased for higher levels (Figure 1).
3.4 | Application of models to severe hypoglycaemia
The concordance (C)-statistics for severe hypoglycaemia derived from
each documented symptomatic hypoglycaemia model were 0.66 for
model 1 and 0.73 for model 2 at year 1 and were higher in the sup-
portive analyses for all 3 models (0.73-0.75). This moderate predictive
power was echoed at year 4, C-statistics being 0.67 in model 1, 0.76
in model 2 and 0.68 to 0.79 in the supportive analyses. The models
were all highly statistically significant (P < .0001).
4 | DISCUSSION
This analysis of hypoglycaemia and its associations contributes data
of clinical interest in 4 main areas, all derived from a large
TABLE 1 Number and proportion of participants with
hypoglycaemia and event rate (events/person in the 6-month
period) over 4 years, by type of hypoglycaemia and the insulin
regimen used in each year
Insulin regimen Year 1 Year 2 Year 3 Year 4
Documented symptomatic hypoglycaemia – any time
Basal
n (%) 170 (15.0) 148 (15.5) 108 (13.3) 100 (14.9)
Event rate 0.82 (4.08) 0.96 (4.31) 0.81 (3.04) 1.22 (4.67)
Basal + mealtime
n (%) 122 (21.4) 141 (21.2) 133 (18.5) 138 (18.6)
Event rate 1.38 (6.43) 1.16 (5.85) 1.00 (3.60) 1.03 (3.62)
Mealtime
n (%) 17 (19.3) 13 (20.0) 10 (16.9) 8 (14.8)
Event rate 0.61 (1.67) 1.12 (4.09) 0.39 (0.93) 0.94 (4.25)
Premixed
n (%) 156 (21.3) 138 (20.4) 113 (18.7) 109 (19.1)
Event rate 1.13 (4.05) 1.09 (4.53) 0.92 (3.33) 1.02 (3.57)
Alla
n (%) 504 (18.5) 471(18.3) 390 (16.1) 376 (16.6)
Event rate 1.05 (4.62) 1.03 (4.76) 0.85 (3.17) 1.03 (3.88)
Documented symptomatic nocturnal hypoglycaemia
Basal
n (%) 66 (5.9) 52 (5.5) 49 (6.0) 47 (7.0)
Event rate 0.14 (0.94) 0.11 (0.62) 0.14 (0.71) 0.23 (1.15)
Basal + mealtime
n (%) 34 (6.0) 47 (7.1) 39 (5.4) 58 (7.9)
Event rate 0.14 (0.73) 0.21 (1.34) 0.14 (0.78) 0.25 (1.27)
Mealtime
n (%) 0 4 (6.2) 1 (1.7) 1 (1.9)
Event rate 0.00 (0.00) 0.31 (1.52) 0.02 (0.13) 0.28 (2.06)
Premixed
n (%) 36 (4.9) 29 (4.3) 34 (5.6) 29 (5.1)
Event rate 0.15 (1.05) 0.10 (0.62) 0.17 (1.03) 0.18 (1.11)
Alla
n (%) 146 (5.4) 136 (5.3) 125 (5.2) 144 (6.4)
Event rate 0.14 (0.94) 0.13 (0.88) 0.13 (0.79) 0.21 (1.17)
Severe hypoglycaemia
Basal
n (%) 23 (2.0) 25 (2.6) 27 (3.3) 22 (3.3)
Event rate 0.03 (0.22) 0.05 (0.40) 0.08 (0.59) 0.15 (1.02)
Basal + mealtime
n (%) 16 (2.8) 14 (2.1) 17 (2.4) 19 (2.6)
Event rate 0.07 (0.69) 0.04 (0.29) 0.07 (0.64) 0.09 (0.91)
Mealtime
n (%) 0 (0.0) 1 (1.5) 1 (1.7) 3 (5.6)
(Continues)
TABLE 1 (Continued)
Insulin regimen Year 1 Year 2 Year 3 Year 4
Event rate 0.00 (0.00) 0.02 (0.12) 0.03 (0.26) 0.22 (1.37)
Premixed
n (%) 10 (1.4) 3 (0.4) 4 (0.7) 2 (0.3)
Event rate 0.03 (0.35) 0.00 (0.07) 0.01 (0.23) 0.00 (0.06)
Alla
n (%) 51 (1.9) 44 (1.7) 49 (2.0) 46 (2.0)
Event rate 0.04 (0.42) 0.03 (0.33) 0.05 (0.50) 0.08 (0.79)
Severe nocturnal hypoglycaemia
Basal
n (%) 11 (1.0) 9 (0.9) 11 (1.3) 15 (2.2)
Event rate 0.01 (0.12) 0.01 (0.19) 0.01 (0.13) 0.03 (0.27)
Basal + mealtime
n (%) 7 (1.2) 9 (1.3) 8 (1.1) 9 (1.2)
Event rate 0.04 (0.64) 0.01 (0.12) 0.02 (0.22) 0.02 (0.21)
Mealtime
n (%) 0 1 (1.5) 0 2 (3.7)
Event rate 0.00 (0.00) 0.02 (0.12) 0.00 (0.00) 0.17 (1.09)
Premixed
n (%) 1 (0.1) 0 1 (0.2) 0
Event rate 0.00 (0.04) 0.00 (0.00) 0.00 (0.04) 0.00 (0.00)
Alla
n (%) 20 (0.7) 19 (0.7) 20 (0.8) 26 (1.1)
Event rate 0.01 (0.31) 0.01 (0.13) 0.01 (0.14) 0.02 (0.25)
Event rates are mean (SD). All values are for the last 6 months of
the year.
a Includes regimens included in the Table, plus other and no insulin.
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multinational non-interventional cohort followed for 4 years after
starting insulin and collected pragmatically from usual clinical care.
We describe the incidence of hypoglycaemia, predictors and in-study
explanatory factors for such events, their relationship to the trajec-
tory of HbA1c and relationship with insulin regimen. We have previ-
ously described the evolution of individually chosen insulin regimens
TABLE 2 Univariate analysisa of documented symptomatic hypoglycaemia at year 1
With
hypoglycaemia (n = 504)
Without hypoglycaemia
(n = 2225)
ORa (95% CI) P
Baseline variables, n (%)
Weight, kg; per 5 kg 76.3 (18.3) 80.4 (18.9) 0.94 (0.91, 0.97) .0002
BMI, kg/m2 28.0 (6.1) 29.6 (6.3) 0.95 (0.94, 0.97) <.0001
Starting total insulin dose, U/kg/d; per 0.1 U/kg/d 0.28 (0.18) 0.25 (0.17) 1.10 (1.04, 1.16) .0009
Family history of type 2 diabetes, n (%)
Yes (n = 1396) 277 (19.9) 1119 (80.2) 1.27 (1.04, 1.55) .0183
No (n = 1307) 221 (16.9) 1086 (83.1) Reference
Prior high blood pressure, n (%)
Yes (n = 1882) 325 (17.3) 1557 (82.7) 0.80 (0.64, 0.98) .0345
No (n = 845) 179 (21.2) 666 (78.8) Reference
Physical activity, n (%)
No (n = 1422) 221 (15.5) 1201 (84.5) 0.67 (0.55, 0.82) .0001
Yes (n = 1296) 282 (21.8) 1014 (78.2) Reference
Baseline insulin regimen, n (%)
Basal (n = 1400) 219 (15.6) 1181 (84.4) Reference .0024
Basal + mealtime (n = 391) 82 (21.0) 309 (79.0) 1.47 (1.09, 1.99)
Mealtime (n = 211) 41 (19.4) 170 (80.6) 1.36 (0.90, 2.06)
Premixed (n = 633) 140 (22.1) 493 (77.9) 1.58 (1.22, 2.04)
Other (n = 94) 22 (23.4) 72 (76.6) 1.95 (1.15, 3.29)
Oral agents, n (%)
None (n = 829) 195 (23.5) 634 (76.5) Reference <.0001
No sulphonylurea (n = 695) 111 (16.0) 584 (84.0) 0.64 (0.49, 0.84)
Sulphonylurea (n = 1205) 198 (16.4) 1007 (83.6) 0.60 (0.48, 0.76)
Physician starting insulin, n (%)
Non-primary care (n = 2394) 465 (19.4) 1929 (80.6) 1.63 (1.14, 2.34) .0076
Primary care (n = 335) 39 (11.6) 296 (88.4) Reference
Variables at 1 year, mean (SD)
Weight, kg; per 5 kg 79.1 (18.4) 82.3 (19.0) 0.96 (0.93, 0.99) .0102
BMI, kg/m2 28.9 (6.0) 30.3 (6.3) 0.96 (0.94, 0.98) .0001
HbA1c, %-units 7.3 (1.2) 7.8 (1.4) 0.76 (0.70, 0.82) <.0001
HbA1c change, %-units −2.1 (2.2) −1.8 (2.0) 0.93 (0.89–0.98] .0041
Fasting plasma glucose, mmol/L 7.5 (2.2) 8.1 (2.6) 0.92 (0.87, 0.96) .0003
Total insulin dose, U/kg/d; per 0.1 U/kg/d 0.44 (0.24) 0.42 (0.25) 1.05 (1.01, 1.09) .0249
Insulin regimen, n (%)
Basal (n = 1130) 170 (15.0) 960 (85.0) Reference .0013
Basal + mealtime (n = 569) 122 (21.4) 447 (78.6) 1.57 (1.21, 2.05)
Mealtime (n = 88) 17 (19.3) 71 (80.7) 1.40 (0.78, 2.52)
Premixed (n = 734) 156 (21.3) 578 (78.7) 1.52 (1.17, 1.98)
Other (n = 152) 34 (22.4) 118 (77.6) 1.78 (1.15, 2.76)
None (n = 56) 5 (8.9) 51 (91.1) 0.57 (0.22, 1.47)
Oral agents (vs none), n (%)
None (n = 986) 213 (21.6) 773 (78.4) Reference .0003
No sulphonylurea (n = 909) 128 (14.1) 781 (85.9) 0.60 (0.47, 0.77)
Sulphonylurea (n = 834) 163 (19.5) 671 (80.5) 0.84 (0.66, 1.07)
DBP, mm Hg, mean (SD) 77.8 (9.9) 79.3 (10.3) 0.85 (0.77, 0.95) .0030
Abbreviatins: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; OR, odds ratio; SD, standard
deviation. Mean (SD) or n (%).
a Controlled for geographical region.
HOME ET AL. 925
and their relation to glucose control,13 together with analyses of pre-
dictors of weight change, glucose control and a description of the
relationship of the latter to cardiovascular events.14–16
The pragmatic, real-life study design may have a limitation with
regard to data acquisition, as hypoglycaemia is poorly identified and
recorded in usual clinical practice; however, this may mean that our anal-
ysis is focused on events more important to people with diabetes, and
thus not forgotten. Accordingly we limited data collection to the
6 months before the annual clinical visits, a period similar to the
26 weeks often used in phase III clinical studies. In this context, 6-month
incidence (proportion of people affected) was not high at ~16% to 19%,
and with no evidence of deterioration of rate over 4 years (numerically a
decrease), in contrast to what might have been expected with the move
to more complex insulin regimens and with increased duration of diabe-
tes.13 An explanation for this may be that individuals were actively man-
aged to avoid hypoglycaemia; certainly, there was considerable change
in individual insulin regimen.13 The incidence results are consistent with
reviews of studies on starting insulin (17% over 6 months18) and the
ORIGIN study (28% over 6 years19), but both those studies used lower
glucose thresholds and would thus be expected to give somewhat lower
rates. Our findings are higher than in those of some registry studies
which may identify only more severe episodes,20,21 and much lower than
the extraordinarily high rates in another study where daily recording
might have led to a positive ascertainment bias.22 Severe hypoglycaemia
was ~2% overall in 6 months, again did not deteriorate in incidence over
4 years, and again matches or contrasts with results from the studies just
referenced.
Event rates for documented symptomatic hypoglycaemia were ~1.0
per 6 months (Table 1), implying an average > 5 events for each person
having at least one episode. A similar issue pertains to severe hypogly-
caemia where the average was ~2 per person experiencing at least one
event, but here the event rate showed signs of rising from years 2 to
4, being ~4 events per person at 4 years, despite the unchanged inci-
dence. Nocturnal hypoglycaemia at ~5% to 6% was ~30% of the inci-
dence of anytime hypoglycaemia, but event rates were just one-sixth of
the incidence of anytime hypoglcaemia. Interestingly, nocturnal severe
hypoglycaemia was proportionately lower in incidence compared with
anytime severe hypoglycaemia than was nocturnal documented symp-
tomatic hypoglycaemia compared with anytime documented symptom-
atic hypoglycaemia, being ~15%, although the latter was subject to
considerable uncertainties because of small numbers.
Baseline predictors of documented symptomatic hypoglycaemia
were not unexpected, either in light of previous studies or clinical
practice. These then included lower body weight/BMI, being more
physically active and presence of micro- and/or macrovascular dis-
ease. However, renal function did not appear important, probably
because of the modest levels of renal impairment found in our study
population. Blood pressure (prior and SBP or DBP) was notably prom-
inent and remained in the multivariate analyses, with the OR for SBP
equivalent to a > 20% increase per 10 mm at 4 years. These may be
acting as surrogates for macrovascular disease. The latter is an associ-
ation reported for severe hypoglycaemia in many studies,23,24 and is
supported by the non-linear relationship of OR, which only rises sig-
nificantly at DBP >95 mm Hg on multivariable analysis. Use of renin-
angiotensin system blockers may also be a factor.
Therapy-based predictors and explanatory factors (oral agents
and insulin regimen type) were mainly present in the year 1 univariate
analysis. Insulin regimen type at 4 years was a univariate explanatory
factor for documented symptomatic hypoglycaemia, but the OR con-
fidence intervals for the major contrasts (premixed vs basal, multiple
injection vs basal) did not exclude 1.00. The explanation is again likely
to be appropriate glucose control management, partly neutralizing
the effects of insulin regimens (or combinations with oral agents)
and/or insulin dosage giving hypoglycaemic problems. Any associa-
tions with oral agents, either at baseline or year 1, also disappeared
by year 4, even though baseline use of sulphonylurea when compared
with no baseline therapy was carried through on multivariable ana-
lyses and showed lower OR compared with no therapy. At first this
might seem paradoxical because use of sulphonylureas with insulin
has been associated with excess hypoglycaemia in 2 studies,18,19 and
indeed documented symptomatic hypoglycaemia with oral agent use
without sulphonylureas affected a numerically higher proportion of
people. The explanation may be in the comparator data for no oral
agent where the risk of hypoglycaemia was marginally higher than in
the sulphonylurea group. It is possible that these people required
more aggressive insulin dosing early on (in year 1) to achieve required
glucose control, while judicious use of sulphonylureas provided some
enhancement of islet β-cell function which, in turn, damped any
erratic insulin action arising for varying absorption from the subcuta-
neous tissue depot.
The relationship of hypoglycaemia to achieved glucose control
is controversial, notably after the identification in the ACCORD
intensive arm of higher severe hypoglycaemia rates in those at
higher HbA1c levels.25 Many studies did not find any
relationship,20,26 although the ORIGIN study (for documented symp-
tomatic hypoglycaemia)19 and the review by Karl et al18 found more
hypoglycaemia at lower attained HbA1c. There was also no relation-
ship with current HbA1c in the standard control group in ACCORD,
with a similar HbA1c to our own findings.25 In the present study,
we found lower attained HbA1c and higher change from baseline in
HbA1c to be significant univariate associations with documented
symptomatic hypoglycaemia. At year 1 this effect was retained on
multivariate analysis, with odds of 25% per %-unit of HbA1c. At
year 4, updated current HbA1c was also retained as a risk factor,
with the OR having a non-linear relationship to HbA1c, but such
that at around an HbA1c of 7.5% (58 mmol/mol) the OR was falling
~10% to 20% per %-unit. These findings and the literature can
probably be reconciled. When titration is forced as in the ACCORD
study, it seems vulnerable people with other medical conditions
become stuck at higher levels of HbA1c with excess rates of hypo-
glycaemia. In more normal care, hypoglycaemia may determine
attained HbA1c level (“treat-to-hypoglycaemia”), and in these cir-
cumstances hypoglycaemia rates may eventually become the same
at all levels of HbA1c. The study population in CREDIT, however,
appears to have been more actively managed, judged by the exten-
sive changes to insulin regimens and increasing insulin doses,13 and
then people managed more closely to normal levels will be at higher
risk of hypoglycaemia. This may affect in particular regimens con-
taining mealtime insulin, with selective moves away from basal +
mealtime and premixed regimens accounting for the reduction in
926 HOME ET AL.
odds ratios compared with basal between years 1 and 4, indeed
becoming non-statistically significant.
Lastly, dose on starting insulin was still a significant factor at year
1, as was actual insulin dose at the time, and the latter was retained
as an independent factor on multivariable analyses, when the ORs
suggest an increase of ~10% in risk per 0.1 U/kg/d dose difference.
This decreased to ~5% at 4 years in model 2 and was not retained in
model 3, and would again appear to suggest the issue was mitigated
over time with appropriate clinical management.
For severe hypoglycaemia, we recognized that our data would be
too sparse in people with type 2 diabetes to perform the same asso-
ciative analyses, with inevitable overfitting and model optimism. We
therefore examined whether the models developed from the whole
dataset would perform adequately when populated with the severe
hypoglycaemia data alone. This proved true of all the models devel-
oped from both the 1-year and 4-year data, with C-statistics (0.66-
0.79) suggestive of moderate to good prediction. Two corollaries
would appear to be that the models developed for documented
symptomatic hypoglycaemia are themselves important, being verified
with a different set of data, and that occurrence of documented
symptomatic hypoglycaemia is itself a useful predictor of severe
hypoglycaemia. This would suggest that therapy approaches shown
to reduce documented symptomatic hypoglycaemia should reduce
severe hypoglycaemia, consistent with the DEVOTE study findings.27
As noted above, the present study has limitations related to
ascertainment, although with the incidence data matching other stud-
ies18,19 the problem is much smaller than found in database studies.
Non-database studies do, however, inevitably involve some patient
selection, consequent on-site selection. As we note above this popu-
lation appears to be relatively actively managed, although not as
intensively as treat-to-target or intensive therapy studies, and the
findings may not be generalizable to situations where insulin therapy
is less optimally managed. Furthermore, the motivators of clinical
decision-making for each individual were not recorded (or indeed
easy to record), so how hypoglycaemia rates were stopped from ris-
ing with increasing duration of diabetes and higher insulin doses over
4 years is unclear. Methodologically, we did define candidate vari-
ables for correlation (univariate) analysis in order to reduce risks from
TABLE 3 Univariate analysisa of documented symptomatic hypoglycaemia at year 4
With hypoglycaemia (N = 376) Without hypoglycaemia (N = 1895) ORa (95% CI) P
Baseline variables
Mean (SD) weight, kg; per 5 kg 77.3 (17.7) 79.8 (18.8) 0.94 (0.91, 0.98) .0025
Mean (SD) BMI, kg/m2 28.4 (5.8) 29.5 (6.2) 0.96 (0.94, 0.98) .0003
Physical activity, n (%)
No (n = 1144) 157 (13.7) 987 (86.3) 0.69 (0.55, 0.87) .0019
Yes (n = 1118) 218 (19.5) 900 (80.5) Reference
Mean (SD) SBP, mm Hg; per 10 mm Hg 142.0 (20.8) 138.8 (18.8) 1.08 (1.02, 1.15) .0079
Mean (SD) DBP, mm Hg 82.7 (12.8) 81.0 (11.3) Non-linear .0004
Mean (SD) HbA1c, %-units 9.3 (1.9) 9.6 (1.9) 0.90 (0.85, 0.96) .0023
Microvascular disease, n (%)
Yes (n = 1607) 292 (18.2) 1315 (81.8) 1.37 (1.04, 1.81) .0234
No (n = 664) 84 (12.7) 580 (87.3) Reference
Macrovascular disease, n (%)
Yes (n = 792) 160 (20.2) 632 (79.8) 1.43 (1.14, 1.80) .0023
No (n = 1479) 216 (14.6) 1263 (85.4) Reference
Variables at 4 years
Mean (SD) weight change, kg; per 5 kg 3.8 (7.6) 2.4 (7.5) 1.14 (1.05, 1.23) .0010
Mean (SD) HbA1c, %-units 7.3 (1.0) 7.6 (1.3) Non-linear .0031
Mean (SD) HbA1c change, %-units −2.0 (2.0) −2.0 (2.2) Non-linear .0100
Insulin regimen, n (%)
Basal (n = 671) 100 (14.9) 571 (85.1) Reference .0034
Basal + mealtime (n = 741) 138 (18.6) 603 (81.4) 1.31 (0.98, 1.75)
Mealtime (n = 54) 8 (14.8) 46 (85.2) 1.07 (0.48, 2.38)
Premixed (n = 571) 109 (19.1) 462 (80.9) 1.37 (1.00, 1.86)
Other (n = 114) 18 (15.8) 96 (84.2) 1.10 (0.63, 1.94)
None (n = 120) 3 (2.5) 117 (97.5) 0.15 (0.05, 0.49)
Mean (SD) SBP, mm Hg; per 10 mm Hg 139.3 (17.1) 135.1 (16.2) 1.19 (1.11, 1.27) <.0001
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; OR, odds ratio; SBP, systolic blood pressure.
a Controlled for geographical region.
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over-fitting, and although these included all those variables known
from the literature (and others), it remains possible some factor of
significance was missing. Furthermore some variables of potential
interest, such as non-cardiovascular morbidities and social
functioning,24,28 were not included nor collected for our analysis.
In conclusion, documented and severe hypoglycaemia occurred
at significant but not high rates in people with type 2 diabetes who
started on insulin therapy. Rates did not change over 4 years despite
increased insulin dosage and duration of diabetes, and indeed the
association with insulin regimen or with oral agent use declined from
year 1 to year 4, perhaps suggesting the problem was addressed by
active clinical management. Predictor and explanatory variables asso-
ciated with hypoglycaemia were largely as expected from clinical
practice and prior publications, and models identified for documented
symptomatic hypoglycaemia worked well when applied to severe
hypoglycaemia. However, achieved HbA1c was still quite strongly
associated with more hypoglycaemia, and this relationship did not
wane with time.
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